Kodiak Sciences Inc (KOD): Price and Financial Metrics
GET POWR RATINGS... FREE!
KOD Stock Price Chart Interactive Chart >
KOD Price/Volume Stats
| Current price | $7.60 | 52-week high | $26.39 |
| Prev. close | $7.74 | 52-week low | $4.90 |
| Day low | $7.34 | Volume | 396,000 |
| Day high | $7.91 | Avg. volume | 1,521,988 |
| 50-day MA | $9.85 | Dividend yield | N/A |
| 200-day MA | $9.62 | Market Cap | 395.50M |
Kodiak Sciences Inc (KOD) Company Bio
Kodiak Sciences is a clinical stage biopharma specializing in therapeutics to treat chronic retinal diseases. The company was founded in 2005 and is based in New York City, New York.
Latest KOD News From Around the Web
Below are the latest news stories about KODIAK SCIENCES INC that investors may wish to consider to help them evaluate KOD as an investment opportunity.
Owning 44% shares,institutional owners seem interested in Kodiak Sciences Inc. (NASDAQ:KOD),If you want to know who really controls Kodiak Sciences Inc. ( NASDAQ:KOD ), then you'll have to look at the makeup of... |
Why Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report?Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare ConferenceKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 2022 Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 14, 2022, at 1:05 p.m. Pacific Time (4:05 p.m. Eastern Time). |
Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's WhyKodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases. |
Kodiak Sciences (KOD) Focuses on Developing Eye Drug TarcocimabKodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe. |
KOD Price Returns
| 1-mo | -25.12% |
| 3-mo | -6.75% |
| 6-mo | 3.12% |
| 1-year | -61.42% |
| 3-year | 173.38% |
| 5-year | N/A |
| YTD | -55.18% |
| 2021 | -42.29% |
| 2020 | 104.18% |
| 2019 | 913.38% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...